FDA cuts off use of GSK's Covid treat­ment in al­most half of the US as BA.2 spreads

With the rise of the Omi­cron sis­ter vari­ant BA.2, Glax­o­SmithK­line and Vir Biotech­nol­o­gy’s cru­cial mon­o­clon­al an­ti­body — one of on­ly two mAbs still be­ing shipped by …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER